CSIMarket
 


Pmv Pharmaceuticals Inc   (PMVP)
Other Ticker:  
 
 

PMVP's Capital Expenditures Growth by Quarter and Year

Pmv Pharmaceuticals Inc 's Capital Expenditures results by quarter and year




PMVP Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 2.21 0.00 0.00
III Quarter September 0.04 2.78 0.50 0.00
II Quarter June 0.86 3.44 0.47 0.00
I Quarter March 0.00 -0.64 0.12 0.00
FY   0.90 7.79 1.09 0.00



PMVP Capital Expenditures third quarter 2023 Y/Y Growth Comment
Pmv Pharmaceuticals Inc reported drop in Capital Expenditures in the third quarter 2023 by -98.42% to $ 0.04 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Pmv Pharmaceuticals Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures decline of -28.38%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Capital Expenditures growth. While Pmv Pharmaceuticals Inc ' s Capital Expenditures meltdown of -98.42% ranks overall at the positon no. 166 in the third quarter 2023.




PMVP Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September -98.42 % 456 % - -
II Quarter June -75 % 631.91 % - -
I Quarter March - - - -
FY   - 614.68 % - -

Financial Statements
Pmv Pharmaceuticals Inc 's third quarter 2023 Capital Expenditures $ 0.04 millions PMVP's Income Statement
Pmv Pharmaceuticals Inc 's third quarter 2022 Capital Expenditures $ 2.78 millions Quarterly PMVP's Income Statement
New: More PMVP's historic Capital Expenditures Growth >>


PMVP Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -20.5 % - -
III Quarter September -94.88 % -19.19 % 6.38 % -
II Quarter June - - 291.67 % -
I Quarter March - - - -
FY (Year on Year)   - 614.68 % - -




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #39
Overall #166

Capital Expenditures Y/Y Growth Statistics
High Average Low
351.46 % -28.38 % -768.33 %
(Jun 30 2022)   (Mar 31 2022)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #39
Overall #166
Capital Expenditures Y/Y Growth Statistics
High Average Low
351.46 % -28.38 % -768.33 %
(Jun 30 2022)   (Mar 31 2022)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Pmv Pharmaceuticals Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
288.33 % 10.24 % -100 %
(Jun 30 2021)  


PMVP's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Pmv Pharmaceuticals Inc realized fall in Capital Expenditures sequentially by -94.88% to $ 0.04 millions, from $ 0.86 millions released in the previous quarter.

But that's not huge issue, as Capital Expenditures generally seem to slow in this quarter.

Within Major Pharmaceutical Preparations industry 157 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Pmv Pharmaceuticals Inc 's Capital Expenditures growth quarter on quarter, overall rank is 2451.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #158
Healthcare Sector #420
Overall #2451
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #158
Healthcare Sector #420
Overall #2451
Capital Expenditures Q/Q Growth Statistics
High Average Low
288.33 % 10.24 % -100 %
(Jun 30 2021)  


PMVP's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Pmv Pharmaceuticals Inc disclosed fall in Capital Expenditures from the second quarter by -94.88% to $ 0.04 millions, from $ 0.86 millions released in the previous reporting period.

If you look into present downturn at the III. Quarter, you should assume, that frequently III. Quarter performance appear to be weaker then in the quarter before

Within Major Pharmaceutical Preparations industry 157 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Pmv Pharmaceuticals Inc 's Capital Expenditures growth quarter on quarter, overall rank is 2451.


Pmv Pharmaceuticals Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 7.79 $ 4.45
Y / Y Capital Expenditures Growth (TTM) - - - - 331.75 %
Year on Year Capital Expenditures Growth Overall Ranking # 35 # 53 # 33 # 61 # 60
Seqeuential Capital Expenditures Change (TTM) - - - 75.13 % 105.21 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 166 # 228 # 244 # 262 # 76




Cumulative Capital Expenditures growth Comment
In the Sep 30 2023 period, Pmv Pharmaceuticals Inc 's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Among companies within the Healthcare sector 14 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 35, from total ranking in previous quarter at 53.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
351.46 %
-28.38 %
-768.33 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 14
Healthcare Sector # 15
Overall # 35

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
351.46 %
-28.38 %
-768.33 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 14
Sector # 39
S&P 500 # 166
Cumulative Capital Expenditures growth Comment
In the Sep 30 2023 period, Pmv Pharmaceuticals Inc 's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Among companies within the Healthcare sector 14 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 35, from total ranking in previous quarter at 53.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
351.46 %
-28.38 %
-768.33 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 14
Healthcare Sector # 15
Overall # 35

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
351.46 %
-28.38 %
-768.33 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 14
Sector # 39
S&P 500 # 166




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
PMVP's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for PMVP's Competitors
Capital Expenditures Growth for Pmv Pharmaceuticals Inc 's Suppliers
Capital Expenditures Growth for PMVP's Customers

You may also want to know
PMVP's Annual Growth Rates PMVP's Profitability Ratios PMVP's Asset Turnover Ratio PMVP's Dividend Growth
PMVP's Roe PMVP's Valuation Ratios PMVP's Financial Strength Ratios PMVP's Dividend Payout Ratio
PMVP's Roa PMVP's Inventory Turnover Ratio PMVP's Growth Rates PMVP's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Encompass Health Corporation-0.54%$ -0.542 millions
Myriad Genetics Inc -1.13%$ -1.130 millions
Opgen inc -1.22%$ -1.220 millions
Avantor Inc -3.33%$ -3.333 millions
United Therapeutics Corporation-4.51%$ -4.506 millions
Enanta Pharmaceuticals Inc-4.80%$ -4.802 millions
Davita Inc -5.46%$ -5.463 millions
Science 37 Holdings Inc -5.63%$ -5.630 millions
Cutera Inc -5.71%$ -5.708 millions
Zoetis Inc -5.84%$ -5.844 millions
U S Physical Therapy Inc-6.25%$ -6.248 millions
Generation Bio Co -6.30%$ -6.298 millions
Ngm Biopharmaceuticals Inc -6.45%$ -6.452 millions
Becton Dickinson And Company-6.67%$ -6.667 millions
3m Company-6.90%$ -6.897 millions
Apyx Medical Corporation-7.45%$ -7.447 millions
Edwards Lifesciences Corporation-7.68%$ -7.679 millions
Viatris Inc -7.70%$ -7.700 millions
Luna Innovations Inc-8.23%$ -8.232 millions
Nevro Corp -8.38%$ -8.377 millions
Shockwave Medical Inc -8.65%$ -8.649 millions
Sonendo Inc -8.86%$ -8.861 millions
Charles River Laboratories International inc -8.90%$ -8.904 millions
Nautilus Biotechnology Inc -9.24%$ -9.242 millions
Harvard Bioscience Inc-9.28%$ -9.276 millions
Fulgent Genetics Inc -9.42%$ -9.420 millions
Idexx Laboratories Inc-9.53%$ -9.529 millions
Sage Therapeutics Inc -9.89%$ -9.890 millions
Caredx Inc -10.40%$ -10.400 millions
Quest Diagnostics Inc-11.02%$ -11.017 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com